VistaGen, Capsant To Co-market Stem Cell-based Drug Screening Platforms | GenomeWeb

NEW YORK (GenomeWeb News) — VistaGen will offer its stem cell-based screening platform with Capsant's cell culture system under a commercialization agreement focused on technologies for new programs that would use stem cell technologies to change the clinical trial process, VistaGen said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.